Novel Eye Serum Reduces Dark Circles by 48% in 6-Week Clinical Trial
Multi-ingredient topical formulation with niacinamide and tranexamic acid shows significant improvement in periorbital hyperpigmentation.
Summary
Researchers tested a novel eye serum containing niacinamide, arbutin, tranexamic acid, and other active ingredients on 53 participants with under-eye dark circles. After 6 weeks of twice-daily application, the formulation reduced hyperpigmentation by an average of 47.94% with no adverse effects. The study used objective digital imaging analysis to measure melanin concentration changes. A separate safety study of 20 volunteers confirmed the product's tolerability and cosmetic benefits, with 76% reporting more uniform skin complexion and 67% noting brighter, lighter-appearing skin around the eyes.
Detailed Summary
Dark circles under the eyes affect millions of people and result from multiple factors including aging, melanin accumulation, and poor blood circulation. While many treatments target only tyrosinase enzyme activity, this study evaluated a comprehensive multi-ingredient approach to address the complex causes of periorbital hyperpigmentation.
Researchers conducted an open-label study with 53 participants who had visible under-eye dark circles across diverse skin types (Fitzpatrick types 1-6). Participants applied a novel serum containing niacinamide, natural arbutin, tranexamic acid, ubiquinone (CoQ10), DHEA derivatives, curcuma extract, and marine exopolysaccharides twice daily for 6 weeks. The team used the Aram Huvis API 100 digital skin analysis camera with specialized CMOS sensors to objectively measure melanin concentration at baseline and 6 weeks.
The results were striking: participants achieved an average 47.94% reduction in under-eye hyperpigmentation, with right eyes showing 48.44% improvement and left eyes 47.43% improvement. Statistical analysis revealed highly significant changes (p<0.0001) for both eyes. Individual responses varied widely, with some participants achieving up to 95% reduction while others showed minimal change. Importantly, no adverse effects were reported during the 6-week treatment period.
A separate safety study by an independent laboratory confirmed these findings in 20 female volunteers. The cosmetic efficacy questionnaire revealed that 76% experienced more uniform skin complexion, 67% noted brighter and lighter skin, and 95% found the product left skin soft and smooth. The formulation's multi-target approach addresses melanin synthesis, oxidative stress, inflammation, and skin structure simultaneously.
While promising, this study has limitations including its open-label design without a placebo control group and relatively short duration. The research was also industry-sponsored, though conducted at an independent medical institution. These findings suggest that combination topical therapies may offer superior results compared to single-ingredient approaches for treating periorbital hyperpigmentation.
Key Findings
- Average 47.94% reduction in under-eye hyperpigmentation after 6 weeks of twice-daily application (p<0.0001)
- Right eye hyperpigmentation decreased by 48.44% and left eye by 47.43% on average
- Zero adverse events reported among all 53 study participants during 6-week treatment period
- 76% of safety study participants reported more uniform skin complexion around eyes
- 67% experienced brighter, lighter-appearing skin and 95% found skin became softer and smoother
- Individual responses ranged from 0% to 95% reduction in pigmentation scores
- Study included diverse skin types from Fitzpatrick Type 1 (9%) to Type 6 (9%) participants
Methodology
Open-label, single-arm prospective study of 53 adults with visible under-eye dark circles applying multi-ingredient serum twice daily for 6 weeks. Objective measurements used Aram Huvis API 100 digital skin analysis camera with CMOS sensors to quantify melanin concentration at baseline and endpoint. Statistical analysis performed using GraphPad Prism with one-way ANOVA and Bonferroni test, significance set at p<0.05. Separate safety study conducted by independent laboratory on 20 female volunteers.
Study Limitations
Study used open-label design without placebo control group, limiting ability to account for placebo effects or natural variation. Six-week duration may not capture long-term efficacy or safety. Research was industry-sponsored, though conducted at independent medical institution. Wide variation in individual responses (0-95% improvement) suggests treatment may not be universally effective. Study did not compare against existing standard treatments or evaluate optimal treatment duration.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.